Neurogene Inc expected to post a loss of $1.06 a share - Earnings Preview
06/05/2025 14:38
Neurogene Inc NGNE.OQ NGNE.O is expected to show no change in quarterly revenue when it reports results on May 8 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Neurogene Inc is for a loss of $1.06 per share. The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Neurogene Inc is $46.00, above its last closing price of $15.11. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -1.13 | -0.99 | Beat | 12.4 | |
| Sep. 30 2024 | -1.22 | -1.22 | -1.19 | Beat | 2.6 |
| Jun. 30 2024 | -1.04 | -1.05 | -1.09 | Missed | -3.8 |
| Mar. 31 2024 | -1.12 | -1.13 | -1.00 | Beat | 11.9 |
| Dec. 31 2023 | -1.17 | -1.17 | -1.51 | Missed | -28.7 |
| -1.64 | | ||||
| -0.80 | |||||
| Mar. 31 2023 | -2.51 | -2.50 | -5.12 | Missed | -104.8 |
Recent news on Neurogene
See all newsBrief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable